Business Context and Reporting Period
This Form 8-K Current Report from Inhibikase Therapeutics, Inc. (IKT) covers events occurring on April 11, 2025, and April 14, 2025. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer (CFO) and the appointment of a successor.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements and employment terms.
- Outgoing CFO Severance/Consulting: Garth Lees-Rolfe will receive a monthly consulting fee of $33,333.00 until August 15, 2025, or earlier termination.
- Outgoing CFO Equity: Options to purchase 61,945 shares continue to vest during the consulting period; vested awards remain exercisable through the end of 2025.
- Incoming CFO Compensation: David McIntyre receives an annual base salary of $485,000 and is eligible for a performance-based cash bonus up to 45% of base salary.
- Incoming CFO Equity: Granted 3,142,967 stock options (1,775,539 Hire Options and 1,367,428 Warrant Adjustment Options), vesting over four years.
Material Changes
The primary material change is the transition of the Company's financial leadership:
- Departure: Garth Lees-Rolfe resigned as CFO, Principal Financial Officer, and Principal Accounting Officer effective April 11, 2025. The resignation was not due to any dispute with the Company or Board.
- Appointment: David McIntyre was appointed as CFO, Principal Financial Officer, and Principal Accounting Officer effective April 14, 2025.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of market risks. Management commentary is limited to the background of the new CFO and the terms of the separation and employment agreements.
- Unusual Items: The appointment includes a specific tranche of "Warrant Adjustment Options" (1,367,428 shares) that become exercisable proportionally to the exercise of Series A-1 and Series B-1 Warrants.
- Contingencies: The new CFO's employment agreement includes severance provisions for termination without Cause or for Good Reason, including 12 months of base salary and health insurance contributions.
Investor Verification Checklist
- Verify the terms of the Consulting Agreement (Exhibit 99.1) regarding the $33,333 monthly fee and vesting schedule for Garth Lees-Rolfe.
- Review the Employment Agreement (Exhibit 99.2) to understand the vesting conditions for the 3.14 million options granted to David McIntyre, specifically the "Warrant Adjustment Options."
- Confirm the effective dates of the leadership transition (April 11 departure vs. April 14 appointment) to assess any interim gaps in financial oversight.
- Check the press release (Exhibit 99.3) for any additional context on the strategic rationale for the leadership change.